title: Non-arteritic anterior ischemic optic neuropathy (NA-AION) after intravitreal injection of bevacizumab (Avastin) for treatment of angoid streaks in pseudoxanthoma elasticum.
abstract: BACKGROUND
  To report a case of nonarteritic anterior ischemic optic neuropathy (NA-AION) following intravitreal injection of bevacizumab (Avastin).
  
  
  METHODS
  Interventional case report with an 18-month follow-up.
  
  
  RESULTS
  A 51-year-old male with pseudoxanthoma elasticum presented with NA-AION 2 weeks after treatment with intravitreal of bevazicumab (Avastin) for choroidal neovascularisation secondary to angioid streaks. Except from a small optic disc without cupping he did not show further risk factors.
  
  
  CONCLUSIONS
  Risk of NA-AION should be taken into consideration when deciding for intravitreal application of drugs including anti-vascular endothelial growth factors (VEGF) agents like bevacizumab (Avastin) in the treatment of retinal vascular diseases.
authors.affiliation: Center of Ophthalmology, University of Tübingen, Schleichstrasse 12, 72076 Tübingen, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Ganssauge
authors.forename: Helmut
authors.initials: H
authors.lastname: Wilhelm
authors.forename: Karl-Ulrich
authors.initials: KU
authors.lastname: Bartz-Schmidt
authors.forename: Sabine
authors.initials: S
authors.lastname: Aisenbrey
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000793:Angioid Streaks / Q000175:diagnosis / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001167:Arteritis / Q000139:chemically induced; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000139:chemically induced* / Q000175:diagnosis; D011561:Pseudoxanthoma Elasticum / Q000150:complications*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab